Gynecologic Cancers

Dr. Chi very nicely reviews the history of operative laparoscopy in gynecologic oncology and covers most of the applications currently considered to be useful.

Minimally invasive surgery is simply the use of small incisions with specialized equipment to accomplish surgical objectives that would otherwise be completed through larger incisions with conventional equipment. A priority of gyne-cologic oncologists

One of the cornerstones of gynecologic cancer surgery is the assessment and removal of the retroperitoneal lymph nodes. Numerous reports have demonstrated that, when performed by highly skilled individuals, laparoscopic

SAN FRANCISCO-A major intergroup phase III study reported at the 30th Annual Meeting of the Society of Gynecologic Oncologists has shown that adding chemotherapy to radiation therapy improves the overall survival rate for women with high-risk early-stage cervical cancer. William A. Peters III, MD, of the Puget Sound Oncology Consortium, Seattle, reported the results on behalf of researchers from the Southwest Oncology Group, Gynecologic Oncology Group, and Radiation Therapy Oncology Group.

BETHESDA, Md-The National Cancer Institute (NCI) has recommended that oncologists use a combination of chemotherapy and radiation instead of radiation alone to treat invasive cervical cancer.

The National Cancer Institute (NCI) recently sent a clinical announcement to thousands of physicians stating that strong consideration should be given to adding chemotherapy to radiation therapy in the treatment of invasive cervical cancer.

NetMed, Inc., a developer and marketer of medical and health-related technologies, announced the commencement of a multicenter US clinical trial of the PAPNET cervical cancer detection system as a primary screening test for Pap smears. The

Several studies have evaluated the use of irinotecan (CPT-11 [Camptosar]), a topoisomerase inhibitor, in the treatment of refractory or recurrent cervical cancer. Various schedules have been used. Response rates have

Endometrial cancer is the most common type of female genital cancer in the United States, with an estimated 32,000 new cases and 5,600 deaths per year. During the first half of the 20th century, the incidence of cervical cancer was greater than

Invasive cancer of the uterine cervix is either the leading or second leading cause of death from cancer among women worldwide and is the leading cause of death from cancer among women in developing countries. In some developing

The World Health Organization (WHO) and European Organization on Genital Infection and Neoplasia (EUROGIN) have

Naturally occurring variants in human papillomavirus type 16 (HPV16) may put infected women at differing levels of risk for

BETHESDA, Md--A review of 10 years' experience with HIV-infected patients treated at University Hospital, Newark, NJ, revealed significantly elevated levels of several types of cancers, but a surprising dearth of invasive cervical cancers, which prompted the study's lead author to suggest dropping cervical cancer from the list of AIDS-associated malignancies.

Carcinoma of the cervix is one of the most common malignancies in women, accounting for 15,700 new cases and 4,900 deaths in the United States each year. Worldwide, cervical cancer is second only to breast cancer as the most common

VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group (GCCG) has challenged the assumption that aggressive combination chemotherapy is worthwhile in chemotherapy-naïve women with metastatic squamous cell cancer of the cervix.

A total of 18 studies have been published concerning the possible relationship of tamoxifen to endometrial

For women diagnosed with stage I cervical cancer during pregnancy who are torn between the desire to maintain a healthy pregnancy and the need for cancer treatment, a recent study offers hope that both desires can be achieved. The study,

WASHINGTON--For the first time since its inception in 1991, funds from the Breast and Cervical Cancer Early Detection Program will flow to all 50 states in fiscal 1997, the Department of Health and Human Services announced.

An expert panel of nine international cancer researchers and practicing oncologists met in Boston to discuss the past, present, and future uses of antiestrogens in the treatment of breast cancer. The first article in this series, based on the symposium presentations, focused on the optimal duration of tamoxifen use (October 1996). This month, the panel explores the noncancer benefits of tamoxifen, as well as the potential risk of endometrial cancer. The symposium was sponsored by Zeneca Pharmaceuticals.

In their comprehensive review of changing concepts in the management of endometrial cancer, Drs. Karasek and Faul highlight the contemporary approach to the management of patients with endometrial adenocarcinoma. The authors stress the evolution

The authors present the major issues and controversies surrounding the treatment of endometrial cancer. A variety of therapeutic approaches have been used in the past, including surgery alone, preoperative radiation and surgery, surgery and

Endometrial carcinoma was a clinically staged disease until the late 1980s, at which point, staging changed to a surgicopathologically defined system. This change in staging, in turn, altered the clinical management of this

NEW ORLEANS--In a phase I trial from M.D. Anderson Cancer Center, the chemopreventive agent difluorometh-ylornithine (DFMO) produced significant regression of cervical intraepithelial neoplasia (CIN) grade 3, Michele Follen Mitchell, MD, reported at the Society of Gynecologic Oncologists meeting.

Cervical cancer's slow, noticeable growth makes it "an ideal disease" for screening, but poor choices--like not getting a Pap smear or having unprotected sex as young adults--give the disease a disastrous head start, a University of Wisconsin Medical

SEATTLE-A group of breast cancer patients treated with tamoxifen (Nolvadex) outside of clinical trials had up to a 60% reduction in their risk of developing cancer in the contralateral breast and no increased risk of ovarian or endometrial cancer, report Linda S. Cook, PhD, and her colleagues at the Fred Hutchinson Cancer Research Center.